Trading Sections
Quince Therapeutics: Strategic Restart Focuses on Rare Lung Diseases for Investors
The acquisition of Orphai Therapeutics signifies a shift towards rare lung diseases and opens new market...
Ciena: Optical Networks as a Crucial Bottleneck in AI Expansion - Evercore ISI Upgrades to "Outperform" and Significantly Raises Price Target!
The business model of Ciena (CIEN) (i.) focuses on optical networks, which form an essential basis for...
Cue Biopharma: Dual Antibody Approach Targets Growth Market for Allergies - B. Riley Sees Over 100% Upside Potential
Strategic focus on functional therapies for autoimmune and allergic diseases. B. Riley initiates coverage...
Ciena: AI Investments as Drivers for a New Margin Level by 2029 - Rosenblatt Confirms Buy Recommendation with Target Price at $525
The business model of Ciena Corp. (CIEN) benefits from increasing demand for optical networks driven...
Definium Therapeutics: Phase 3 data paves the way for a $13.2 billion market - Bank of America sees around 130% price potential
Definium Therapeutics (DFTX) focuses on psychedelic-based medications for brain disorders, thereby addressing...
Iren Ltd.: JPMorgan Sees a Price Target of $65 and the Nvidia Alliance Shapes the Market!
JPMorgan upgrades Iren Ltd. (IREN) to "Overweight" and sees a price target of $65. The business model...
Pyxis Oncology: Wells Fargo Sees 2 Billion USD Peak Revenue for New Cancer Drug MICVO
Wells Fargo raises the price target for Pyxis Oncology (PYXS) to 19 USD based on recent study data,...
Lithium Americas Corp.: The 1.6 Billion USD Investment Aimed at Securing America's Supply Chains - Experts See 100% Price Potential
JPMorgan sees a 100% upside potential due to raised lithium price assumptions and sets the price target...
Climb Bio: How a modified antibody could change the market for kidney diseases
Climb Bio (CLYM) focuses on its lead product CLYM116 aimed at the addressable market for IgA Nephropathy...
Alibaba: Specific Payback Cycles and a $175 Price Target Bring AI Cloud into Focus
Alibaba (BABA) is increasingly focusing on the expansion of AI infrastructure and cloud services, funded...
Ionis Pharmaceuticals: A Rare Milestone and the Strategic Shift in Neurology - Experts See 98% Share Price Potential!
The FDA approval for Zanvastro, 19 days before the PDUFA date, opens the door to an untapped market for...
Fuelcell Energy: Price Target of 30 USD Meets Billion-Dollar Order Backlog
The strategic focus on data centers drives the order backlog of Fuelcell Energy (FCEL) to over 3.6 billion...
Fervo Energy Company: 400 MW Contract with Google and Over 150% Upside Potential!
Fervo Energy (FRVO) employs modified drilling techniques for weather-independent, emissions-free geothermal...
Latigo Biotherapeutics: Guggenheim's buy recommendation with over 100% upside potential draws attention to NaV1.8 inhibitors
Latigo Biotherapeutics (LTGO) focuses on non-opioid analgesics for acute and chronic pain. On September...
Attovia Therapeutics Inc.: Leerink Initiates Coverage on Stock After Successful IPO with Price Target of $52!
Attovia Therapeutics (ATTO) develops complex biologics for immune-mediated diseases using its proprietary...
Iren Ltd.: From Post-Earnings Sell-Off to $90 Target - H.C. Wainwright Sees a Buying Opportunity
Iren Ltd. (IREN) is undergoing a strategic shift from Bitcoin mining to AI cloud infrastructure. The...
Zymeworks Inc.: FDA approval for Ziihera triggers target price increase to 55 USD and milestone payment
The business model of Zymeworks Inc. (ZYME) combines internal research with strategic partners, relieving...
Methode Electronics: Data Center Expansion and E-Mobility as Revenue Drivers - Craig-Hallum Sets Target Price of $30
Craig -Hallum rates Methode Electronics (MEI) on August 25 with a buy recommendation and a target price...
Shattuck Labs: Raymond James sees the DR3 antibody as a growth driver - Expert sees 130% price potential
Raymond James has assigned a "Strong Buy" rating to the stock of Shattuck Labs (STTK) and has set an...
Ultragenyx: The first FDA approval in the gene therapy segment - Experts raise the price target to $103!
The US health authority FDA has granted accelerated approval for the gene therapy Genglycos by Ultragenyx...
Nuvation Bio: Hidden Valuation Reserves in the Precision Oncology Sector?
Nuvation Bio (NUVB) looks at a strong Q2 and liquidity of $661 million. JPMorgan initiated coverage on...
adesso SE: AI contracts worth €73 million bring industry discount into focus - Berenberg sees 121% price potential
Analysts at the private bank Berenberg see a price target of €128 for adesso SE (i.) and point to the...
Eton Pharmaceuticals: 99% Revenue Jump from Rare Diseases and the Path to a 35% Margin
The focus of Eton Pharmaceuticals (ETON) on therapeutics for rare diseases led to a revenue growth of...